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Background: Improving adherence to ocular hypertension (OH)/glaucoma therapy is highly likely to prevent or
reduce progression of optic nerve damage. The present study used a behaviour change counselling intervention to
determine whether education and support was beneficial and cost-effective in improving adherence with glaucoma
therapy.
Methods: A randomised controlled trial with a 13-month recruitment and 8-month follow-up period was conducted.
Patients with OH/glaucoma attending a glaucoma clinic and starting treatment with travoprost were approached.
Participants were randomised into two groups and adherence was measured over 8 months, using an electronic
monitoring device (Travalert® dosing aid, TDA). The control group received standard clinical care, and the intervention
group received a novel glaucoma education and motivational support package using behaviour change counselling.
Cost-effectiveness framework analysis was used to estimate any potential cost benefit of improving adherence.
Results: Two hundred and eight patients were recruited (102 intervention, 106 control). No significant difference in
mean adherence over the monitoring period was identified with 77.2% (CI, 73.0, 81.4) for the control group and 74.8%
(CI, 69.7, 79.9) for the intervention group (p = 0.47). Similarly, there was no significant difference in percentage
intraocular pressure reduction; 27.6% (CI, 23.5, 31.7) for the control group and 25.3% (CI, 21.06, 29.54) for the
intervention group (p = 0.45). Participants in the intervention group were more satisfied with information about
glaucoma medication with a mean score of 14.47/17 (CI, 13.85, 15.0) compared with control group which was 8.51
(CI, 7.72, 9.30). The mean intervention cost per patient was GB£10.35 (<US$16) and not cost-effective.
Conclusions: Adherence with travoprost was high and not further increased by the intervention. Nevertheless, the
study demonstrated that provision of information, tailored to the individual, was inexpensive and able to achieve high
patient satisfaction with respect to information about glaucoma medication. Measurement of adherence remains
problematic since awareness of study participation may cause a change in participant behaviour.
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Sub-optimal adherence to prescribed glaucoma therapy is
associated with progressive visual field loss and unnecessary
additional prescribing or surgery [1]. A cross-sectional glau-
coma study has found that participants with adherence
rates less than 80% have worse visual field defects than
those with greater adherence rates [2].
Patients that have a stronger belief in the necessity for
eye drops are more adherent [3] and studies that have tar-
geted patient beliefs have been effective in improving ad-
herence [4,5]. Conversely, whilst poor glaucoma education
has been cited as an explanation for non-adherence to
therapy [6-8], interventions that purely focus on providing
education have failed to achieve significant improvement
in adherence [9-11]. However, studies using multifaceted
intervention components including education and tailor-
ing of information, and encouraging patients to discuss
strategies for incorporating the medication administration
into their daily activities, have detected a significant im-
provement in adherence [12,13].
Thus, the aim of the present study was to determine
whether an intervention designed to both target beliefs
and provide tailored education about glaucoma and its
management by using a behaviour change counselling
(BCC) technique [14], could be beneficial and cost-effective
in improving adherence with topical therapy. The inter-
vention was designed to address the multifactorial nature
of unintentional and intentional non-adherence [15]. The
design, justification of such an intervention and method-
ology of outcome measures is the subject of a previous
published protocol paper by the same authors [16]. Previ-
ous research with the same patient population highlighted
that an intervention that provided glaucoma and treat-
ment information and motivational support was required
at the point of medication initiation [7]. Therefore, para-
mount to the design of the intervention was the feasibility
of the randomisation and delivery of the intervention dur-
ing the same clinic visit as initiation of treatment and an
8 month follow-up period to establish the longevity of any
intervention effect on adherence.
Methods
Sample and setting
The Norwich Adherence Glaucoma Study (NAGS) was a
randomised controlled trial conducted in the Glaucoma
Clinic of a UK National Health Service (NHS) teaching
hospital. The study received ethical approval from the
Norfolk Research Ethics Committee, UK. A summary of
the methods are provided since the full details have been
described previously [16].
Patient recruitment, randomisation and blinding
Consecutive patients newly initiated onto travoprost mono-
therapy for the treatment of primary open angle glaucoma(POAG), ocular hypertension (OH) or glaucoma suspect
using the European Glaucoma Society Guidelines [17], were
invited to participate; no financial stipend or travoprost
samples were given, and patients collected their own repeat
prescription for travoprost as per standard UK practice.
Patients interested in study participation were referred
by their clinician to the research staff and were in-
formed that they may be randomised to either the
standard care or the intervention group (allocation ratio
1:1), and that their adherence to travoprost would be
monitored for the study duration. No standardized
script was used during recruitment.
Participants giving written consent were randomised,
stratified by diagnosis (either POAG, or OH/glaucoma sus-
pect) and experience of the glaucoma service (new patient
or follow-up patient but commencing active treatment) by
research staff using a centralized automated telephone ran-
domisation system. Given the interventional nature of the
study, patients and research staff were not masked to their
intervention allocation, but clinicians were masked as to
which patients were participating in the study. The stat-
istician (AC) was also masked to which data belonged to
the intervention/control group during analysis. Once
randomised, all participants were followed through to
study completion regardless of changes to therapy, in-
cluding travoprost discontinuation.
Basic demographic information were collected for non-
consenting patients.
Study design
Five nurses/research technicians working within the
glaucoma clinic were trained to deliver the intervention
and study related tasks as previously described [16]; they
were titled ‘Glaucoma Support Assistants (GSAs)’ during
the study. Two of the five GSAs were Glaucoma Special-
ist Nurses delivering routine nurse-led glaucoma patient
review clinics. The GSA specialist nurses separated split
roles by delivering routine care three days a week and
undertaking the GSA role on one separate day a week.
To prevent the roles of GSAs influencing the provision
of routine care, administrative staff ensured that partic-
ipants did not attend nurse-led follow-up glaucoma
clinics run by nurses with split roles. Furthermore, pre-
randomisation, patients were unlikely to have received
care from the GSA nurses as Glaucoma Specialist Nurses
do not prescribe medication and would not have been ex-
posed to patients newly requiring treatment.
The control
Standard care was provided which involved appropriate
tests to establish POAG/OH diagnosis and initiation of
treatment if indicated before entering the study. All par-
ticipants received basic information and leaflets about
glaucoma as deemed appropriate by their clinicians, who
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accordance with standard clinical protocols.The intervention
Before leaving the Glaucoma Clinic, intervention partici-
pants received an individualised glaucoma education and
motivational support package using BCC from a GSA.
The development and standardisation of the interven-
tion has been previously described [16]. A telephone
advice-line from Monday to Friday, 9 am–5 pm was pro-
vided by the GSAs to respond to glaucoma related quer-
ies from participants and their carers.Data sources: adherence monitoring,
questionnaires, medical records and interviews
Travalert® dosing aid (TDA)
The Travalert® dosing aid (TDA, Alcon Laboratories, Inc.,
Forth Worth, TX, USA) was used to collect adherence
data from all participants. Each participant had their ad-
herence calculated using a computer programme specific-
ally designed for the purpose. The Steering Committee for
the study, which included glaucoma specialist clinicians,
adherence experts, a patient using eye drops for glaucoma
and public representative, discussed and agreed what
would determine an adherent dose; at least one recorded
application (regardless of bi- or uni-lateral dosing) within
a 4-hour window either side of an individual’s average dos-
ing time; the mean of each daily dose administered be-
tween 5 pm and 5 am was calculated for the duration of
the study period. Eye drop application using the TDA was
demonstrated to all participants by a GSA, irrespective of
group allocation. New TDAs were dispensed at visit-2
(2 months) if the GSA found the battery or TDA to have
failed during patient use.Questionnaires
A participant self-administered questionnaire was com-
pleted after visits-1 (study initiation), 2 (2 months) and 3
(8 months) and returned by post. The questionnaire in-
cluded self-reported satisfaction with information received
about Travoprost using the validated ‘Satisfaction with
Information about Medicines Scale’ (SIMS) [18]. SIMS
comprises 17 questions which are detailed in Figure 1
and scores range from 0 to 17 with high scores indicat-
ing greater satisfaction.Medical records
Glaucoma Clinic held records were accessed for IOP
measured by Goldmann tonometry at baseline, and visit-
3 (8 months) plus co-morbidity data which was classified
using the Charlson Co-morbidity Index [19].Interviews
A structured interview undertaken at the time of recruit-
ment was used to collect patient age, ethnicity (classified
by participants), index of multiple deprivation (IMD)
(a UK specific measure of relative deprivation using
postal addresses), type of housing, educational qualifica-
tions and family history of glaucoma; these characteris-
tics were used to describe the participant population
and explore predictors of adherence (not reported in this
publication).
Primary outcomes
Adherence was determined using the number of adher-
ent doses using electronic monitoring divided by the ex-
pected number of doses for the monitoring period for
both the total 8 month study duration and the final
2 months of follow-up [16]. Additionally, a dichotomous
classification of adherence score based on the final
2 months of follow-up was used (‘adherent’ if the aver-
age number of TDA recorded doses was ≥80% of ex-
pected and ‘non-adherent’ if <80%).
Secondary outcomes
The IOP measure for each treated eye was used as a
clinical outcome measure. The percentage reduction in
IOP from baseline and visit-3 was calculated and com-
pared between intervention and control groups.
The SIMS score was used to establish differences be-
tween the control and intervention groups’ satisfaction
with information received about their medication. The
SIMS score was also used compared with participants
adherence score to ascertain if satisfaction with informa-
tion improved adherence to medication.
Health economic measures
A resource log book captured all Glaucoma Clinic care
activity and GSA time spent with each participant deliv-
ering the education and support package, in addition to
answering any queries on the telephone helpline. Patient
costs were excluded from the study. The health eco-
nomic analysis was based upon the NHS for England
perspective. The primary outcome measure was incre-
mental hospital cost per percentage gain in adherence.
The specific costs associated with secondary care oph-
thalmic activity were identified on review of the patient
pathway by an expert clinician (DCB), glaucoma health
care professional (HC), and health economist (RF). The
costs captured in the resource logs were described using
direct hospital treatment costs [16].
Missing data
Missing data were imputed using a multivariate normal
imputation model after suitable transformations, to en-
sure that the variables were normally distributed. A
Figure 1 Comparison of the control and intervention group SIMS at visit 1 categorised according to items that relate to potential
problems with travoprost and action and usage of travoprost.
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of missing data. The results (not shown) indicated that
results were not sensitive to the missing data.
Therapist bias
Since the intervention was intended to improve adher-
ence by motivating patient behaviour, all GSA interven-
tions were examined to test for any potential ‘therapist
bias’. Interventions were grouped by the GSA delivering
the intervention and the number of adherent partici-
pants per GSA compared using a Chi-squared test. Any
GSA showing greater or lesser adherence outcome per
participant, may have suggested a potential significant
bias in the way that an individual GSA had delivered the
intervention to their allocated participants.
Statistical analysis
Descriptive statistics were used to characterise the
demographics of the study population. All analyses were
based on an intention-to-treat principle.The primary analysis compared the percentage of inter-
vention and control group ‘adherers’ using a Chi-squared
test for the total 8 months of follow-up and separately for
the final 2 months. Additionally, the combined month-7
and −8 post-randomisation percentage adherence values
were analysed using a Student’s t-test to compare the
intervention and control group. A repeated measures
analysis-of-variance (ANOVA) was carried out (with time
measured in months) to assess for any difference between
intervention and control over time.
Reduction in IOP, and SIMS were compared between
the control and intervention groups using Student’s
t-tests and at different time points (SIMS and IOP at
visit-1, visit-2 and visit-3) to compare any differences.
Adherence was correlated with SIMS using a Spearman’s
rank correlation coefficient (SRCC) test.
The difference in total costs and adherence percentage
was calculated incrementally between the intervention
and control group to provide the incremental cost effect-
iveness ratio (ICER) of additional adherence from the
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formed on the base case ICER using patient variability in
cost and outcome to determine the robustness of the
economic analysis.
Sample size
At the time of calculating the sample size, there was less
available data to suggest likely adherence rates with once
daily glaucoma medication [20] and limited research to
indicate the effect of an intervention on adherence. Thus
sample size estimates were derived from general medi-
cine where average non-adherence rates of 25% have
been reported [21,22]. Available data at the time for
glaucoma adherence studies using medication monitors
had shorter follow-up time and more complicated dos-
ing regimens than the proposed study [23,24]. Therefore,
without a comparable study, a 20% increase in adher-
ence was estimated and adherence defined as ≥ 80% of
expected doses recorded by the TDA. Assuming an ad-
herence rate of 60% in the control group and 80% in the
intervention group, 81 people in each group provided
80% power to detect a difference using a Chi-squared
test with 5% significance. Based on an estimated 20%
drop-out a target of 200 participants was set.
Results
Eligible participants were recruited from November
2009 for 13 months as illustrated in Figure 2. Previous
use of glaucoma therapy was the most frequent reason
for exclusion. There was no suggestion that the failure
of the TDA device differed between those who were ad-
herent and those who were not. Furthermore, partici-
pants who changed treatment were not associated with
poorer adherence.
The demographic characteristics of the sample popula-
tion are summarised in Table 1 and were evenly bal-
anced. The participants were predominantly of white
British ethnicity and, at the time of recruitment, had
been diagnosed with POAG as opposed to OH or glau-
coma suspect. The cohort was evenly matched as to
whether they were new patients or had been seen previ-
ously in the Glaucoma Clinic. There were no statistically
significant differences in age (p = 0.257), gender (p =
0.253) and IMD (p = 0.379) between study participants
and the 46 individuals who declined participation.
There were no significant differences between ob-
served and imputed data, thus all analyses were con-
ducted on observed data and there were no therapist
effects (Chi-Squared p = 0.860).
Mean adherence over the total 8-month monitoring
period was slightly greater in the control group (77.2%),
but the difference (2.4%; 95% CI, −4.2, 9.0) between the
two groups was small and not statistically significant
(p = 0.471). There was also no difference in the meanadherence for the final 2 months of monitoring which
was 79.3% in the control group, the difference (1.6%;
95% CI, −6.8, 10.0) between the two groups being min-
imal (p = 0.703). There was no statistically significant dif-
ference in the proportion of individuals with ≥ 80%
adherence (p = 0.631) between the two groups: control
group 62.5% and intervention group 66.7%. A repeated
measures analysis of percentage adherence rate for each
month found no difference in adherence between the
two groups (p = 0.685) or any interaction between
month and group (p = 0.894), the details of which are
provided in Figure 3.
Intraocular pressure
The mean IOP at baseline for subsequently treated right
and/or left eyes was 23.7 mmHg (95% CI, 22.6, 24.8) for
the control group and 22.4 mmHg (95% CI, 21.3, 23.5)
for the intervention group which was not statistically
different (p = 0.096, 1.3, CI −0.2, 2.9). There was no sig-
nificant difference in percentage reduction in IOP from
baseline to visit-3 between the two groups with control
group being 27.6% (SD, 19.2) and intervention group be-
ing 25.3% (SD 19.7) (2.3 mean difference, CI −3.6, 8.2,
p = 0.448).
Satisfaction with information about travoprost
SIMS scores for the intervention group were signifi-
cantly higher than the control group at all three time
points post intervention (visit-1 mean score = 14.47 (95%
CI, 13.85, 15.09) for the intervention group and 8.51 for
the control group (95% CI, 7.72, 9.30, p < 0.001). The
same high level of satisfaction was maintained for the
intervention group, whilst control group SIMS score did
increased significantly over time with a difference in
mean score between visit-1 and visit-3 of 2.91, SD 4.74
p = <0.001. SIMS was not significantly related to medica-
tion adherence (r = −0.015 p = 0.883).
Figure 1 provides a comparative illustration of the spe-
cific items of SIMS information that intervention and
control participants felt they lacked and these were cate-
gorised into items related to ‘action and usage’ or ‘poten-
tial problems of travoprost’ [18]. Both groups had a
higher degree of satisfaction with information about ‘ac-
tion and usage of travoprost’ (control group mean aver-
age 65%, intervention group 86%) than the ‘potential
problems’ (control group 33%, intervention group 80%)
but the difference was considerably more marked in the
control group.
Health economic evaluation
The mean intervention cost per participant was GB
£10.35 with a total expenditure GB£746.17 greater than
the control group. Since no significantly greater effect-
iveness was found (percentage gain in adherence) but it
Figure 2 The Consolidated Standards of Reporting Trials diagram including detailed information on excluded participants and missing
TDA data.
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cost-effective.
Discussion
The present trial of an adherence intervention failed to
achieve greater adherence to newly initiated topical glau-
coma treatment. Adherence in the control group was
considerably higher than the previously reported esti-
mates used in general medicine, that were used in the
present study power calculations [22] and ophthalmol-
ogy [25]. Thus, improving adherence, in an already ad-
herent population, would have been difficult to achieve.Previous studies examining interventions to improve
adherence to glaucoma medication have enrolled pa-
tients identified to be poorly adherent in an attempt to
create the best conditions to measure greater effect sizes
[26] or have measured adherence pre- and post- inter-
vention to make comparison of individual differences
[13]. However, the present study examined the potential
of an intervention to improve adherence at the point of
medication initiation in accordance with previous re-
search findings [7]. Since patients were medication
naïve, targeting unintentionally non-adherent patients
was not feasible. Furthermore, clinical practice at the
Table 1 Baseline characteristics for control and
intervention groups
Control Intervention
N % N %
Gender
Male 58 54.7 47 46.1
Female 48 45.3 55 53.9
Ethnicity
White British 104 98.1 102 100
Other 2 1.9 0 0
Housing tenure
Home owner 92 86.8 82 80.4
Renter (council) 6 5.7 11 10.8
Renter (private) 5 4.7 4 3.9
Other 3 2.8 5 4.9
Marital status
Married/partner 75 70.8 73 71.6
Divorced/separated 5 4.7 7 6.9
Widowed 19 17.9 17 16.7
Single 7 6.6 5 4.9
Highest qualification
GCSE (high school) 44 41.5 45 44.1
A-levels (college) 4 3.8 5 4.9
Degree (graduate school) 11 10.4 8 7.8
Post-graduate 8 7.5 2 2
Other (inc. less than GCSE) 37 34.9 42 41.2
Parents with glaucoma
No 79 74.5 70 68.6
Yes 22 20.08 24 23.5
Not known/no contact 5 4.7 8 7.8
Siblings with glaucoma
No 93 87.7 85 83.3
Yes 8 7.5 9 8.8
Not known/no contact 5 4.7 8 7.8
Children with glaucoma
No 102 96.2 95 93.1
Yes 2 1.9 0 0
Not known/no contact 2 1.9 7 6.9
Diagnosis and new/follow-up care
POAG/NTG new patient 33 31.1 32 31.4
POAG/NTG follow-up patient 40 37.7 37 36.3
GS/OH new patient 16 15.1 15 14.7
GS/OH follow-up patient 17 16.0 18 17.6
Mean SD Mean SD
Age 70.06 10.9 70.7 11.3
Intraocular pressure 23.4 10.9 22.2 5.4
Table 1 Baseline characteristics for control and
intervention groups (Continued)
Charlson score 1.6 2.2 1.5 2.1
Number of medications 2.8 2.9 2.7 2.8
IMD 12.7 7.7 15.4 11.2
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patients likely to have poor adherence [27] and measur-
ing such behaviour would have required several months
to perform and these observational methods often alert
patients to the fact that their behaviour is being moni-
tored which can cause a reactivity bias resulting in in-
creased adherence to medication [28,29]. Thus, it was
neither appropriate nor feasible to target a poorly adher-
ent cohort in the present study.
The present study result may indicate that standard
care offered by an NHS Glaucoma Clinic was sufficient
to promote high adherence with travoprost for the
population studied. An alternative interpretation of the
high level of adherence is that Hawthorne effects may
have occurred, whereby the act of study participation
improved motivation and thus increased adherence in
both groups [26,28,30]. Future studies may benefit from
including a placebo ‘attention’ arm in order to control
for the extra attention that participants receive when
they agree to take part in research. Standardisation of in-
structions given to participants at the time of recruit-
ment may also control for external variances in
measured adherence caused by the way information is
conveyed and comprehended. However, these phenom-
ena are not well documented and further research is re-
quired to establish the extent that study participation
and reactivity to adherence monitoring may inflate ad-
herence relative to the natural environment. Further-
more, studies of adherence may be intrinsically biased
through selection of patients who attend appointments
and engage in healthcare; thus non-adherent patients are
more likely to be missing from the sample and those
agreeing to participate may be more adherent to medica-
tion than those who decline [31].
Another consideration is that the fidelity of interven-
tion delivery may have been compromised. However, as
described in the protocol paper [16], a rigorous training
process for GSAs was undertaken and quality assured by
3 experts in motivational interviewing.
Finally, the intervention may have been flawed in its de-
sign. Since conception of the intervention used in the
present study, the large body of evidence to identify the
domains that explain behaviour change has been collated
into the Theoretical Domains Framework [32,33]. The
present intervention design which was informed by em-
pirical evidence as described in the protocol paper [16]
maps comprehensively onto the Theoretical Domains
020
40
60
80
100
1 2 3 4 5 6 7 8
%
 A
d
h
er
en
ce
Months from baseline
Control
Intervention
Figure 3 Monthly mean % adherence (CI) for control and intervention groups.
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were treatment naïve, after using their eye drops in daily
life, their underlying behavioural processes may have al-
tered. For example, the domain called beliefs about capa-
bilities, is particularly susceptible to change after the
participant has experienced using their eye drops. Whilst
the participant may have felt empowered and capable
within the clinic environment, the home environment
may present new unanticipated challenges. It may there-
fore be appropriate for a subsequent study to include a
second consultation perhaps targeted at non-adherent
participants.
In so far as the authors know, the present study is the
first that has attempted to report 8-months of follow-up
using a TDA. Previous studies have reported that the TDA
accurately records drop administration, but the longest of
these studies was for only a 3-month duration [35-37]. At
month 2 only 10% of the TDA was missing, which sug-
gests it was the longevity of the present study that lead to
the high failure of the TDA. Whilst the failure of the TDA
increased the uncertainty around the adherence estimate,
there was no evidence that the failure of the TDA differed
between those who were adherent and those who were
not, and thus did not bias the results.
Reduction of IOP did not correlate with TDA measured
adherence, most likely due to limitations of the methodo-
logical approach and the pharmacodynamics of prosta-
glandin analogues, rather than conclusive evidence that
the intervention failed to improve IOP control. However,
previous studies using similar methods have also found
that IOP reduction had no relationship to adherence
[13,37]. Assessing IOP due to individual differences (types
of glaucoma and diurnal variance) together with regres-
sion to the mean, led to ‘noisy data’ [38,39]. Better mea-
sures of both adherence and clinical outcomes are neededfor future glaucoma research, but what these might be, re-
mains difficult to establish.
Contrary to evidence from previous studies, whilst the
NAGS intervention group were more satisfied with in-
formation received about travoprost, this had no meas-
urable effect on adherence which may be due to any
number of the reasons already discussed. Since the most
marked difference between intervention and control
groups related to potential problems of using travo-
prost, standard care would appear to require greater in-
formation provision with respect to these aspects, but
whether this would improve adherence has not been
established. The increase over time in information satis-
faction demonstrated by the control group is interesting
and suggests that patients seek/obtain information from
additional sources post treatment initiation or that the
desire for information declines.
The NAGS cost effectiveness analysis was based upon
improvement in adherence between the two groups and
as such the data were dominated by the control treatment.
Utilising a quality-adjusted life-years (QALY) analysis to
measure the impact of the intervention on health may have
provided useful additional information. However, generic
preference instruments such as the Sickness Impact Profile
and Short Form Health Survey-6D were not considered
specific enough to detect the asymptomatic nature of
glaucoma in its early stages. Furthermore, it is unlikely
that glaucoma specific tools would detect patient quality
of life changes associated with early stages of disease in
an 8 month period of follow-up, since in the majority of
treated and monitored patients, disease progression is
slow [40-42].
There is little published evidence to suggest that ad-
herence interventions can consistently improve adher-
ence to medication within the resources available in
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search teams which cannot easily be translated into
clinical practice [22]. However, in this study the inter-
vention was led by specialist nurses and allied health
professionals already working within the hospital eye
service. The economic costs associated with the
provision of the intervention were also based upon
local costs, which provided a more realistic consider-
ation of associated costs. Whilst this gave confidence
in the ease as to how such an intervention could be in-
corporated into clinical practice and its relative cost,
ensuring that there was no contamination between al-
lied health professionals who worked in the Eye Clinic
(and had received enhanced training in motivational
interviewing skills), was more problematic. Every effort
was made to ensure that participants did not come into
contact with GSAs during their follow-up period, but it
was not possible to account for any influences these
staff and the study itself had on routine practices of all
clinical staff during the study period.
The results of the present study relate to a relatively af-
fluent, primarily white British population prescribed glau-
coma mono-therapy, and may not be generalisable to
other populations that may have different cultural prac-
tices. Mono-therapy is also thought to aid adherence, with
more complex regimens being problematic for patients,
[7,43] so the results should not be extrapolated to patients
prescribed dual or multiple therapies. It would be of value
to study the effect of the present intervention on a popula-
tion expected to have lower adherence and using multiple
topical anti-glaucoma therapies.
Whilst a standardised measure for adherence remains
undefined, studies continue to produce heterogeneous ad-
herence results which may be due to variations in adher-
ence measurement, duration of monitoring and definition
of adherence. In the present study, we used multiple mea-
sures and reporting methods of adherence which provided
consistent findings and ensured that comparisons could
be made with studies of shorter duration and those using
differing statistical analyses.
Conclusion
In conclusion, the present study did not demonstrate im-
proved adherence with a behaviour change intervention,
despite the intervention producing high levels of patient
satisfaction. However, whilst previous negative results
have often been under-reported in favour of studies with
significant findings [44] publication of this study, which
was informed by theory plus empirical evidence and ad-
hering to rigorous study methods, is therefore of signifi-
cance to researchers and health professionals in this field.
The model described in the present study requires further
development as a potential service to give better support
to patients prescribed topical glaucoma therapy. However,measurement of adherence itself and determination of the
long-term clinical benefits of improving adherence remain
problematic. In particular, further research is required to
determine the size of any Hawthorne effects. Whilst a
standardised and accurate measure for adherence remains
undefined, future adherence studies may benefit from uti-
lising multiple methods to quantify and classify adherence
in parallel to help clarify true adherence levels.
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